CX717 is an ampakine compound created by Christopher Marrs and Gary Rogers in 1996 at Cortex Pharmaceuticals. It affects the neurotransmitter glutamate...
14 KB (1,512 words) - 18:32, 22 December 2024
this class to date, reportedly some 5x the potency of CX-717. Presently, CX717 is in phase II clinical trials as a possible non-stimulant pharmacotherapy...
9 KB (928 words) - 16:55, 9 June 2024
AMPA receptor AMPA receptor positive allosteric modulators aniracetam, CX717, piracetam AMPA receptor antagonists kynurenic acid, NBQX, topiramate Anandamide...
85 KB (8,412 words) - 16:21, 28 November 2024
clinical trials for CX717 for use as a treatment for Alzheimer’s, ADHD and Sleep disorders. In 2006, The FDA halted clinical trials for CX717 because they feared...
4 KB (349 words) - 03:28, 18 March 2024
agonists (e.g. BIMU8), δ-opioid agonists (e.g. BW373U86) and AMPAkines (e.g. CX717) can all reduce respiratory depression caused by opioids without affecting...
223 KB (19,881 words) - 16:28, 1 January 2025
cell, leading to depolarization and signal transduction. At this time, CX717 is the most successful ampakine in human trials and has very few side effects...
14 KB (1,656 words) - 12:52, 24 January 2024
depression which can be a side effect of opioid analgesic drugs. BIMU8 CX717 Miller TL, Raab LM, Shaffer TH, Schweikert A, Diana F, Fort P, et al. (September...
5 KB (395 words) - 20:51, 6 January 2024
research, sleep deprivation prevention drugs such as Modafinil and Ampakine CX717 have increased in significance. However, because these chemical drugs directly...
45 KB (5,389 words) - 18:11, 15 February 2024